STERIS (STE) Rebound Puts Its Undervalued Narrative To The Test

STERIS (STE) stock has recently drawn attention after its latest share price move, with the company closing at $237.93 on 19 August 2026. Investors are weighing this valuation against its recent performance and financial profile.

See our latest analysis for STERIS.

Over the past month STERIS has seen an 11.15% 1 month share price return and a 10.02% 3 month share price return, although the year to date share price return is down 4.84% and the 1 year total shareholder return is down 3.23%. This points to improving short term momentum against a softer longer term record.

If recent strength in STERIS has you reassessing your watchlist, it could be a good moment to broaden your search and check out 41 healthcare AI stocks.

S TERIS has just pushed higher in the short term while its 1 year return is still slightly in the red. If you are considering an entry, does buying after this rebound make sense, or is patience wiser before the valuation section?

Most Popular Narrative: 9.3% Undervalued

The most followed STERIS valuation narrative places fair value at $262.25 per share compared with the recent close at $237.93. That gap rests on a detailed set of growth and profitability assumptions that go well beyond the recent share price rebound.

Strong growth in order backlog and consistent order intake for both Healthcare and Life Sciences segments signal robust future capital demand, supported by the global aging population and rising demand for infection prevention, likely to drive sustained revenue and earnings growth.

Read the complete narrative.

Curious what is baked into that fair value for STERIS. The narrative leans on steady revenue expansion, higher margins and a future earnings multiple that assumes investors remain willing to pay up for this profile.

Result: Fair Value of $262.25 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, STERIS still faces pressure from higher tariffs on key materials and potential healthcare reimbursement changes, which could squeeze margins and slow customer capital spending.

Find out about the key risks to this STERIS narrative.

Another View on STERIS Using Market Multiples

The narrative suggests STERIS is about 9.3% below fair value at $262.25 per share, yet the current P/E of 28.8x is higher than both the peer average of 24.4x and a fair ratio of 26.4x. That points to a richer pricing profile. Is the market already paying up for quality here, or do earnings expectations still leave room?

For a closer look at how this valuation gap compares with peers, and how the fair ratio might shift over time, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals around STERIS sentiment, it makes sense to move quickly, review the underlying data yourself and weigh both sides of the story. To see both the concerns and the upside that other investors are focused on, take a closer look at the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond STERIS?

If STERIS has sharpened your focus, now is the moment to expand your opportunity set with a few targeted stock ideas built from our screeners.

• Target reliable income streams by reviewing companies flagged as potential 12 dividend fortresses that may suit a dividend-focused watchlist.
• Seek better value candidates by scanning 48 high quality undervalued stocks that could offer attractive combinations of quality and pricing.
• Prioritise capital protection by checking 75 resilient stocks with low risk scores so you are not missing stocks that may align with a more cautious approach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com